Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval

Seres Therapeutics’ SER-109 has faced more setbacks than most drugs, but the biotech has kept the faith and is now tantalizingly close to possibly seeing its candidate become the first FDA-approved oral microbiome therapeutic.